Vanessa Figueroa’s Post

If you were able to attend, you would have found out the true and authentic meaning of the word #Novel, as it pertains to a device/idea/solution etc in #Startups generally, but, in my opinion #MedTech, specifically.

Our #CEO, Sarah Howell, and Professor Thomas Pieber, Principal Investigator on the Phase I #clinicalTrial investigating our ultra-concentrated, ultra-rapid acting #insulin candidate, AT278, in people with Type 2 #diabetes and a high BMI, joined Proactive to discuss the trial’s positive results which were recently presented at the European Association for the Study of Diabetes e.V. (EASD) Annual Meeting, one of the largest global scientific conferences on diabetes.   Sarah and Thomas share their insights on the significance of AT278, what makes it completely unique in the insulin field, its potential for patients and what’s coming next.   To watch the full interview, click here: https://lnkd.in/gp9y-xqc   #Arecor #drugDevelopment #biotech

https://lnkd.in/gaF-uBYq MPSCON2024 - My message on importance of the conference Registration link: https://lnkd.in/gptRJTwP *10th August 2024* is the last date for *submission of Abstract* Important: *TNMC awarded 3 credit points* for the registered participants. This will be applicable for only those registered before *20th Aug 2024* if you need credit points, please register before this. We need to upload the list of registered participants in advance. *Late registration will not qualify for TNMC credit points*. #pharmacology

Highly recommended - I am particularly looking forward to hearing Jesper Lau telling how he and his team made #semaglutide - I.e. the really efficacious #GLP1 agonist which as #Ozempic and #Wegovy de facto is responsible for our current Danish growth and a major part of our GNP and for why lots of prizes are being given to GLP-1 these dans - Medicinal (peptide) chemistry when it is best - paving the way for many other peptide drugs. And if you are into advanced cutting edge molecular and cellular pharmacology Dimitrios Stamou’s will be a treat.

New Featured CE! 🔗 https://bit.ly/4cyaiR6 In this Expert Forum, Dr. Lawrence Tanenbaum, MD, FACR, will review the classification of Gadolinium MR contrast agents according to their molecular structure, ionicity, and stability. The impact of these properties and supporting clinical data for safety considerations in choosing an agent will be discussed with the goal of providing insight that can be applied in everyday clinical practice. Following the presentation questions from the audience were addressed in a moderated Q&A session.

We are back with 'Lessons from the SV95C qualification Series'. In 2023, Sysnav and its partners qualified SV95C, the first digital primary endpoint to the European Medicines Agency (EMA). In the next few months, we'll share our biggest takeaways from the qualification. 🤝 Lesson 2: It takes a village Creating meaningful endpoints requires interaction between physicians, engineers, patient associations, and regulators.  Digital endpoints should be: 👉 Meaningful for patients 👉 Used by clinicians 👉 Trusted by regulators The SV95C EMA qualification is the result of collaboration with University of Oxford, Roche, Parent Project Muscular Dystrophy, Muscular Dystrophy UK, World Duchenne Organization, and many others.

Critical part to our treatment is Dosimetry.

Today, I will be moderating a webinar about all things carrier screening! We have some wonderful speakers Doron M Behar, MD, PhD and Pamela Callum so register at the link below if you’d like to join us. #thermofisheremp #carrierscreening #NGS

It's no April Fool's joke, we are announcing the 2024 HTMA Midwest Symposium! Vendor registration is open now @ www.htma-mw.org. Make sure you follow us here on Linked In for every update! #HTMAMWSymposium #IamHTM #AAMIeXchange24 #MDPublishing #TechNation #MDExpo #ACICertified #HTMA #HTM #healthcaretechnology #BMET #Biomed #ClinicalEngineering #medicaldevices #medicalequipment 

We want to hear from you! What are the latest pharmacogenetics topics you learned about at #ACMGMtg24? Tell the MGS team at Booth #948! Explore more peer-reviewed, clinically relevant, and medically actionable pharmacogenetics articles: https://ow.ly/nJNw50QI3nZ